Clinical Trials Sponsored by Kyowa Hakko Bio Co., Ltd.

Total 480 results

Kyowa Kirin Co., Ltd.

Completed

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Parkinson's Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes Type 2

Japan
Kyowa Kirin Co., Ltd.

Completed

Along-term Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes, Type 2

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of OPC-262 in Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 1 Study of ARQ 197 in Patients With Solid Tumors

Cancer
Kyowa Kirin Co., Ltd.

Completed

Clinical Study of KW-2246 in Patients With Cancer Pain

Pain | Cancer

Japan
Kyowa Kirin Co., Ltd.

Completed

A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor

Anemia

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Parkinson's Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa (6002-009)

Parkinson's Disease

Japan
Kyowa Kirin Co., Ltd.

Completed

Mineral and Bone Disorders Outcomes in Stage 5D of Chronic Kidney Disease (MBD-5D)

End Stage Renal Disease | Hyperparathyroidism, Secondary

Japan
Kyowa Kirin, Inc.

Recruiting

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

Diabetic Macular Edema (DME)

Australia, United States, Japan, Korea, Republic of
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)

X-linked Hypophosphatemia

Netherlands, United States, United Kingdom, France
Kyowa Kirin, Inc.

Active, not recruiting

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Cutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma, Relapsed

United States, United Kingdom, Spain, France, Italy
Kyowa Kirin, Inc.

Completed

Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite

Hepatic Impairment

United States
Kyowa Kirin, Inc.

Completed

Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356

Healthy Male Subjects

United States
Kyowa Kirin, Inc.

Completed

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Cutaneous T-Cell Lymphoma

United States, Spain, France, Australia, Switzerland, United Kingdom, Japan, Denmark, Germany, Italy, Netherlands
Kyowa Kirin, Inc.

Completed

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Parkinson's Disease

United States
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

X-linked Hypophosphatemia

United States, Korea, Republic of, Japan, Ireland, United Kingdom, France, Italy
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)

X-Linked Hypophosphatemia

Korea, Republic of, Canada, United States, Australia, Japan, United Kingdom, Sweden
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Terminated

An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

Parkinson's Disease

United States
Kyowa Kirin, Inc.

Terminated

An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia

Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)

X-Linked Hypophosphatemia

United States
Kyowa Kirin, Inc.

Completed

Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer

Colorectal Cancer

United States
Kyowa Kirin, Inc.

Completed

12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa

Parkinson's Disease

United States
Kyowa Kirin, Inc.

Completed

12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa

Parkinson's Disease

United States
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome

Sleep Disorder | Restless Legs Syndrome

United States
Kyowa Kirin, Inc.

Completed

KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

Carcinoma | Cancer | Solid Tumor

United States, France
Kyowa Kirin, Inc.

Terminated

KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

Urothelial Carcinoma

United States, Spain
Kyowa Kirin, Inc.

Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
Kyowa Kirin, Inc.

Recruiting

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)

United States, Japan, Australia, Korea, Republic of
Kyowa Kirin, Inc.

Completed

Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)

X-Linked Hypophosphatemia

United States
Kyowa Kirin, Inc.

Completed

Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

Tumor Induced Osteomalacia (TIO) | Epidermal Nevus Syndrome (ENS)

United States
Kyowa Kirin, Inc.

Terminated

A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma

Stage IV Melanoma

United States
Kyowa Kirin, Inc.

Terminated

Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United Kingdom
Kyowa Kirin, Inc.

Completed

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

Digestive System Diseases | Gastrointestinal Diseases | Colonic Diseases | Intestinal Diseases | Abdominal Pain | Inflammatory Bowel Diseases | Ulcerative Colitis | Colitis | Colitis, Ulcerative | Autoimmune Disease

Hungary, Russian Federation, Serbia, United States, Poland, Czechia, Romania
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, Germany, Japan
Kyowa Kirin, Inc.

Completed

A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy

Parkinson's Disease

United States
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients

Parkinson's Disease | Movement Disorder Syndrome

United States
Kyowa Kirin, Inc.

Completed

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Adult T-cell Leukemia-Lymphoma

United States, United Kingdom, Belgium, France, Brazil, Peru
Kyowa Kirin, Inc.

Completed

A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa

Parkinson's Disease

United States
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)

X-linked Hypophosphatemia

United States, Korea, Republic of, Canada, Japan, France, Denmark
Kyowa Kirin Pharmaceutical Development Ltd

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age

X-linked Hypophosphatemia (XLH)

Sweden, Spain, United Kingdom, Italy, Austria, France
Kyowa Kirin, Inc.
AstraZeneca

Completed

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

Advanced Solid Tumors

United States
Pfizer
Kyowa Kirin Co., Ltd.

Terminated

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

Advanced/Metastatic Solid Tumors

United States
Kyowa Kirin Co., Ltd.
Ono Pharmaceutical Co. Ltd

Completed

Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors

Solid Tumor

Japan
Bio-innova Co., Ltd

Not yet recruiting

Sildenafil 100 mg Tablets Relative to Viagra 100 mg Tablets

Healthy Subjects
Bio-innova Co., Ltd

Not yet recruiting

Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule

Healthy Subjects
Bio-innova Co., Ltd

Not yet recruiting

Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Relative to Yasmin®

Healthy Subjects
Bio-innova Co., Ltd

Not yet recruiting

Dapagliflozin Tablet 10 mg Relative to Forxiga® Tablets 10 mg (DAP-030-23)

Healthy Subjects
Bio-innova Co., Ltd

Not yet recruiting

Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg (TIC-025-23)

Healthy Subjects

Clinical Trials Sponsored by Kyowa Hakko Bio Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations